Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 5404131, 5 pages
Case Report

Uncovering Clinical Features of De Novo Philadelphia Positive Myelodysplasia

1Baylor St. Luke’s Medical Center, Houston, TX 77030, USA
2Baylor College of Medicine, Section of Hematology and Oncology, 1 Baylor Plaza, Houston, TX 77030, USA
3Department of Pathology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA
4The Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA

Correspondence should be addressed to Gustavo Rivero; ude.mcb@orevirag

Received 30 November 2016; Accepted 24 January 2017; Published 21 February 2017

Academic Editor: Akimichi Ohsaka

Copyright © 2017 Aristides Armas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Myelodysplastic syndrome (MDS) is cytogenetically heterogeneous and retains variable risk for acute myeloid leukemia transformation. Though not yet fully understood, there is an association between genetic abnormalities and defects in gene expression. The functional role for infrequent cytogenetic alteration remains unclear. An uncommon chromosomic abnormality is the presence of the Philadelphia (Ph) chromosome. Here, we report a patient with Ph+ MDS treated with low dose Dasatinib who achieved hematologic response for 7 months. In addition, we also examined the English literature on all de novo Ph + MDS cases between 1996 and 2015 to gain insight into clinical features and outcome.